Articles
Launch excellence: new environment, different challenges

Launch excellence: new environment, different challenges

Following on from the earlier article by IMS Health assessing the need for new commercial models, Sarah Rickwood reviews how product launches have been impacted by the new pharma environment and what companies can do to achieve excellent launches. At a time when fewer new pharmaceutical products are coming to market, companies and investors pin extremely high hopes on those that do...

Articles
The mediKOL brief – will dabigatran replace warfarin?

The mediKOL brief – will dabigatran replace warfarin?

Simon Smyth looks at upcoming competitors to warfarin for the prevention of stroke in patients with atrial fibrillation and asks whether dabigatran, the lead runner, will significantly impact the market. Warfarin is used to prevent strokes in patients with atrial fibrillation. It is the most effective medication approved for this indication, however, for many well documented reasons, patients do not like taking it and physicians do not like prescribing it...

Articles
Talk to them virtually – Online qualitative market research for this century’s pharma (part I)

Talk to them virtually – Online qualitative market research ...

In the first piece of a two part series, Bors Hulesch looks at how online research has developed and how the pharma industry is using these tools today. In the proto-internet era of the mid-1990’s, the market research community was quick to catch on to the opportunities presented by online research. I vividly remember the moment in late 1996, when my team at Ipsos (I spent my apprentice years there) was abuzz with setting up an online agency overnight...

Sales & Marketing

Digital

Market Access

Editor's Picks

  1. AbbVie's Cerevel takeover delivers Parkinson's approval
  2. FDA clears first drug for MCT8 deficiency
  3. Novartis taps China's Abogen for autoimmunity TCE
  4. AZ takes stake in Summit Therapeutics in $2bn deal
  5. PhRMA hires ex-House Majority Leader Eric Cantor as its CEO

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more